Kairos Pharma, LTD. (KAPA) Form 8-K — Jul 22, 2026
Kairos Pharma entered into an Investigator Initiated Research agreement with Bayer to evaluate its lead antibody ENV-105 in combination with Bayer’s XOFIGO for prostate cancer bone metastasis. Under the terms, Bayer will supply the radium drug, while Kairos is solely responsible for initiating, managing, and financing the preclinical study. The collaboration targets a significant market opportunity estimated between $570 million and $1.3 billion. Kairos noted that previous Phase 2 data for ENV-105 showed an 86% clinical benefit rate in resistant metastatic castration-resistant prostate cancer (mCRPC).
Key figures
- Study End Date
- Dec 20, 2026
- Study Start Date
- June 15, 2026
- Addressable Market
- $570M–$1.3B
- Clinical Benefit Rate
- 86%
- Liability Cap Per Year
- $1,000.00
Price after filing
Close on the filing date to close N calendar days later (from $0.31). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.